Nandhini Baskaran, M.Sc.;M.Phil.; Ph.D. student

JAD profile

Affiliation(s): 

Avinashilingam University

Lab URL: 

http://avinuty.ac.in/maincampus/index.php?%2Fscience%2Fbiochemistry

Areas of Interest: 

nanoparticles, Alzheimer disease

Biography & Research: 

Delivering Zn nanoparticles from Camellia sinensis for Alzheimer Disease Introduction The diseases of the central nervous system (CNS) represent one of the fastest growing areas of concern requiring urgent medical attention. Treatment of CNS ailments is hindered owing to different physiological barriers including the blood–brain barrier (BBB), which limits the accessibility of potential drugs. CNS diseases mostly affect components of the brain or the spinal cord. Treatment of CNS disorders is hindered because of the complexity of the blood–brain barrier (BBB) which results in inadequate exposure of the treatment site to pharmaceutical agents, posing a significant threat to human health. The BBB is a dynamic barrier that protects the brain against unwanted substances, as well as being a barrier to drug transport into the brain from the blood circulation (Shah and Amiji 2013). Alzheimer’s disease Alzheimer’s disease (AD) is a progressive, irreversible neurological disorder that occurs gradually and results in memory loss, unusual behavior, personality changes, and loss of the ability to thinking. It is estimated to affect 15 million people worldwide. AD is the cause of dementia in the elderly. AD is a progressive neurological disorder with duration of around 8.5 years between onset of clinical symptoms and death. Bifunctional MNPs that were chemically coupled with Ab1–42 peptide (to image amyloid plaque deposition) and PEG (to improve per-meability in the brain). They have demonstrated that, following administration of MNPs conjugated with PEG and Ab42, the amyloid plaques were detected without injecting any agent gen-erally used for increasing the permeability (Wadghiri et al.2013) Medicinal plant Medicinal plants that have shown the early promising signs of clinical efficacy in the treatment of AD have been investigated. One common feature of these plants is their ability to exert neuroprotective effects through inhibition of AChE or inhibition of oxidative stress. Objective: The objectives of the present study are • To assess the phytochemical and antioxidant activity of Camellia sinensis • To synthesis, optimize and characterize the flavonoid mediated zinc nanoparticles • To assess the dosage and cytotoxic nature of flavonoid mediated zinc nanoparticles • To check and compare in-vitro activity of the anti-Alzheimer’s activity of acetyl cholinesterase and synthesized nanoparticles • To check and compare in-vivo activity of the anti-Alzheimer’s activity of acetyl cholinesterase and synthesized nanoparticles • In silico analysis of the characterized nanoparticles and acetyl cholinesterase Work Plan Phase I: Assessment of phytochemical and antioxidant activity of plant The plant samples were collected and the extract was prepared, the quantitative and qualitative analysis will be s carried out. To identified the active compounds - HPTLC, GCMS Phase II: Synthesis of nanoparticles and Characterization To synthesis of nanoparticles from medicinal plant and they are characterized such as Zeta potential, DLS, FIIR, SEM, TEM, XRD, GCMS, HPTLC, HPLC and NMR. Preparation of Nano capsulation Phase III: Assessment of the Dosage and Cytotoxic nature of the zinc nanoparticles • Assessment of the dosage level and cytotoxic nature of zinc nanoparticles in human PBMC Phase IV: Checking and comparison on Anti-Azheimer’s activity of acetyl cholinesterase and synthesized nanoparticles in-vitro • In-vitro (cell line) 1. Purchase, maintenance and harvest of the cell line 2. Assessment of Antioxidant activity 3. Assessment of Anti- Alzheimer’s activity Phase V: Checking and comparison on Anti-Azheimer’s activity of acetyl cholinesterase and synthesized nanoparticles In-vivo • In-vivo (animal study) 1. Choosing the animal model 2. Purchase and Acclimatization 3. Grouping of animals based on study design 4. Induction of expected Alzheimer’s disease condition 5. Testing the animal model using zinc nanoparticles • Analysis 1. General health, phenotypic and behavioural study, biochemical parameters, antioxidant activity, immunological & histological & histo-pathological assays, Anti- alzheimer’s activity • Comparison of the Anti-Alzheimer’s activity of synthesized nanoparticles and commercial acetyl cholinesterase Phase VI: • In silico analysis of the characterized zinc nanoparticles and acetyl cholinesterase In silico study will be carried out for drug delivery system.